Sotrovimab Biosimilar – Anti-Spike glycoprotein mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb - Research Grade |
|---|---|
| Species | Humanized |
| Expression system | Mammalian cells |
| Purity | >85% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Applications | ELISA,WB |
| Aliases /Synonyms | Sotrovimab ,,Spike glycoprotein,anti-Spike glycoprotein |
| Reference | PX-TA1637 |
| Publications |
|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | Human IgG |
| Clonality | Monoclonal Antibody |
About Sotrovimab biosimilar
Sotrovimab is a neutralizing monoclonal antibody with an activity against SARS-CoV-2 virus in humans. It has been commercialized as XEVUDY by GlaxoSmithKline and Vir Biotechnology, Inc. Sotrovimab is able to bind with Spike protein, which is responsible of the pathogenicity of the Severe Acute Respiratory Syndrome- Coronavirus( SARS-CoV-2).
A treatment by biosimilar recently approved
FDA and EMA have very recently given their approvals for the marketing of Sotrovimab as a treatment against some severe forms of COVID. The epitope targeted by this neutralizing antibody is not mutated in the different variants of SARS-CoV-2 of concern.
About Spike protein
Spike glycoprotein is a transmembrane viral fusion protein. It is known to be paramount in the binding of the virus to the cell during infection process. Spike has a homotrimeric structure and each monomere is composed of two subunits: S1 and S2. The S1 part is carrying the Receptor Binding Domain (RBD), and the S2 part is responsible of the fusion of the virus with the cellular membrane. The RBD Part of S1 is binding the Angiotensin Converting Enzyme 2 (ACE2) in the organism.
A research grade biosimilar
Sotrovimab biosimilar is a dual-action antibody, which is able to to neutralize the virus in vitro, kill infected cells, provide a high barrier to resistance, and achieve high concentrations in the lungs. Proteogenix offers this product for research use only. Sotrovimab is a human-origin monoclonal antibody expressed in a mammalian system (Chinese Hamster Ovaries-CHO).
SDS-PAGE for Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb
Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb, on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb binds to RBD Domain in indirect ELISA Assay
Immobilized RBD Domain (cat. No.PX-COV-P046) at 0.5µg/mL (100µL/well) can bind to Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb (cat. No.PX-TA1637) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450
Related products
![CoV-S[679-833]](data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMzY4IDM2OCIgd2lkdGg9IjM2OCIgaGVpZ2h0PSIzNjgiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyI+PC9zdmc+)
Contact us
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Toshi –
This antibody along with other therapeutic antibodies were tested in surrogate virus neutralization test using spike trimers and ACE2 protein. This antibody did not show weak inhibition of all variants tested (IC50 344.03 ng/mL for Delta, >500 ng/mL for Gamma and Alpha, 244.1 ng/mL for the wild type).
Toshi –
This antibody along with other therapeutic antibodies were tested in surrogate virus neutralization test using spike trimers and ACE2 protein. This antibody did not show weak inhibition of all variants tested (IC50 344.03 ng/mL for Delta, >500 ng/mL for Gamma and Alpha, 244.1 ng/mL for the wild type).